Utilizing emergency departments for pre‐exposure prophylaxis (PrEP)

Update to Interim Guidance for Preexposure Prophylaxis (PrEP) for the Prevention of HIV Infection: PrEP for Injecting Drug Users

On June 12, 2013, the Thailand Ministry of Health and CDC published results from a randomized controlled trial of a daily oral dose of 300 mg of tenofovir disoproxil fumarate (TDF) that showed efficacy in reducing the acquisition of human immunodeficiency virus (HIV) infection among injecting drug users (IDUs) (1). Based on these findings, CDC recommends that preexposure prophylaxis (PrEP) be c...

Preexposure Prophylaxis for HIV Prevention

This interactive feature addresses the diagnosis or management of a clinical case. A case vignette is followed by specific clinical options, none of which can be considered either correct or incorrect. In short essays, experts in the field then argue for each of the options. In the online version of this feature, available at NEJM.org, readers can participate in forming community opinion by cho...

Pre-exposure Prophylaxis (PrEP)

In 2012, the US Food and Drug Administration (FDA) approved Truvada to be used as PrEP by HIV negative people who are at high risk of sexually acquired HIV infection. The US Centre for Disease Control has since developed guidelines and recommended PrEP be used by people at high risk of HIV acquisition via sexual transmission or injection drug use (http://www.cdc.gov/hiv/prevention/research/prep/).

The European preexposure prophylaxis revolution

PURPOSE OF REVIEW The review describes the European epidemic and the challenges in moving from clinical trials of preexposure prophylaxis (PrEP) to routine practice. RECENT FINDINGS Two European trials conducted in gay and other MSM and transgender women reported a high and consistent reduction in HIV incidence using oral PrEP with tenofovir/emtricitabine (TDF/FTC). The incidence of HIV infec...

Ethical challenges of preexposure prophylaxis for HIV.